Почетна › Множен миелом › Arizona
Клинички испитувања за Множен миелом во Arizona
28 студии за Множен миелом бараат учесници на локации во Arizona.
Градови во Arizona
Официјален текст на студијата (англиски)
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
- Mayo Clinic Hospital in Arizona, Phoenix
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 5.10.2026 · NCT06465316Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)
- Mayo Clinic in Arizona, Scottsdale
Се регрутира
Возраст 18 и постари · Сите полови · Ажурирано 1.10.2026 · NCT06630104A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
- City of Hope Phoenix, Goodyear
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 1.10.2026 · NCT07589634A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Gilbert
- Research Site, Tucson
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 29.9.2026 · NCT07391657A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Mayo Clinic Cancer Center-Scottsdale, Phoenix
Се регрутираФаза 4
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT05201781A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Mayo Clinic Phoenix, Phoenix
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT07258511A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Mayo Clinic 1, Phoenix
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT07518186A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
- Mayo Clinic Phoenix, Mayo Clinic Building, Phoenix
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT07393282A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Banner MD Anderson Cancer Center, Gilbert
- University of Arizona Cancer Center, Tucson
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT05552222TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Cancer Treatment Centers of America-Phoenix, Phoenix
Се регрутираФаза 2
Возраст 12 и постари · Сите полови · Ажурирано 22.9.2026 · NCT02693535A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Mayo Clinic Hospital Scottsdale /ID# 278349, Scottsdale
Се регрутираФаза 2/3
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT07095452Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Banner MD Anderson Cancer Center, Gilbert
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 14.9.2026 · NCT06297226Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
- Mayo Clinic Arizona, Phoenix
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 28.8.2026 · NCT06375044Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Cancer Center at Saint Joseph's, Phoenix
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 19.8.2026 · NCT04566328A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
- GSK Investigational Site, Bullhead City
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 19.8.2026 · NCT05714839AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Phoenix
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 17.8.2026 · NCT05850234Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Gilbert
- Research Site, Phoenix
- Research Site, Tucson
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 14.8.2026 · NCT07764978A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
- Banner MD Anderson Cancer Center, Gilbert
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 12.8.2026 · NCT07280013A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- Mayo Clinic - Arizona, Phoenix
- HonorHealth, Scottsdale
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 6.8.2026 · NCT07284758A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
- Mayo Clinic in Arizona - Phoenix, Phoenix
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 16.7.2026 · NCT06121843A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Mayo Clinic Arizona /ID# 251405, Phoenix
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 13.7.2026 · NCT05650632Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Cancer Center at Saint Joseph's, Phoenix
Се регрутираФаза 3
Сите возрасти · Сите полови · Ажурирано 10.6.2026 · NCT05561387A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
- Mayo Clinic in Arizona, Scottsdale
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 10.6.2026 · NCT03017820Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- Banner University Medical Center Tucson, University of Arizona, Phoenix
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 4.6.2026 · NCT05243797Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
- Banner MD Anderson, Gilbert
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 19.5.2026 · NCT06433947A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- GSK Investigational Site, Phoenix
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 22.4.2026 · NCT06679101Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
- Arizona Oncology Associates, Tucson
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 22.4.2026 · NCT05972135A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients
- CTCA at Western Regional Medical Center, Goodyear
Се регрутираНабљудувачка студијаДобредојдени се здрави волонтери
Возраст 18 и постари · Сите полови · Ажурирано 20.2.2026 · NCT07225738Од ClinicalTrials.gov, податоци преземени 6.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.